Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR882 and XOI Co-administration in Uncontrolled Gout
NCT07116746Phase 2Active, not recruiting
- Sponsor
- Arthrosi Therapeutics
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pozdeutinurad in gout, sponsored by Arthrosi Therapeutics. Started Dec 2025; status: active, not recruiting.
02
Drugs
pozdeutinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT07116746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116746.